Nichols & Pratt Advisers LLP MA Buys 7,911 Shares of IQVIA Holdings Inc. $IQV

Nichols & Pratt Advisers LLP MA increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 6.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 131,656 shares of the medical research company’s stock after acquiring an additional 7,911 shares during the quarter. IQVIA comprises about 1.4% of Nichols & Pratt Advisers LLP MA’s holdings, making the stock its 21st biggest holding. Nichols & Pratt Advisers LLP MA’s holdings in IQVIA were worth $22,453,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. purchased a new stake in IQVIA in the 4th quarter worth approximately $25,000. Ascentis Independent Advisors bought a new position in shares of IQVIA in the first quarter worth $25,000. International Assets Investment Management LLC bought a new position in shares of IQVIA in the fourth quarter worth $27,000. Gilpin Wealth Management LLC purchased a new stake in shares of IQVIA in the fourth quarter worth $27,000. Finally, CrossGen Wealth LLC bought a new stake in IQVIA during the fourth quarter valued at $28,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 2.1%

IQV opened at $203.87 on Thursday. The business’s fifty day simple moving average is $179.59 and its 200 day simple moving average is $188.72. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock has a market cap of $34.03 billion, a PE ratio of 25.26, a P/E/G ratio of 1.79 and a beta of 1.20.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has approved a share repurchase plan on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

IQV has been the subject of several recent analyst reports. HSBC restated a “buy” rating and set a $240.00 target price on shares of IQVIA in a research report on Monday. Evercore reiterated an “outperform” rating and set a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Robert W. Baird lifted their target price on shares of IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research report on Wednesday, July 1st. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $223.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.